Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.AWH · Entity 7871 | Interim CEO | December 31, 2024 | January 29, 2025 |
| Gossamer Bio, Inc.GOSS · Entity 6928 | Director | September 23, 2026 | September 25, 2026 |
| Organon & Co.OGN · Entity 4115 | Head of Research & Development | May 04, 2023 | May 08, 2023 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date December 31, 2024 · Filed January 29, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,644 |
Last balance in matching sequence
After 2025-01-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-12-31 · Exercise / conversion · Acquired 20,000 · Balance 20,000 F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on October 28, 2024. Row 2 · 2025-01-08 · Tax withholding · Disposed 6,356 · Balance 13,644 F2: This line reflects the tax withholding on the vesting of RSUs that vested on December 31, 2024. F5: This report is being filed to correct the number of shares held after tax withholding on the vesting of RSUs that vested on December 31, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-12-31 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2024-12-31 · Exercise / conversion · Acquired 20,000 · Balance 0 F3: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F4: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on October 28, 2024.
F2: This line reflects the tax withholding on the vesting of RSUs that vested on December 31, 2024.
F3: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock.
F4: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4.
F5: This report is being filed to correct the number of shares held after tax withholding on the vesting of RSUs that vested on December 31, 2024.
Gossamer Bio, Inc.
Report date September 23, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.99 · Expires 2036-09-22 | Direct | 10,000 |
Reported balance
After 2026-09-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-23 · Grant · Acquired 10,000 · Balance 10,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Organon & Co.
Report date May 04, 2023 · Filed May 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,599 |
Ending reported balance
After 2023-05-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-04 · Exercise / conversion · Acquired 4,984 · Balance 30,767 F1: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Row 2 · 2023-05-04 · Tax withholding · Disposed 2,168 · Balance 28,599 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 4,984 |
Reported balance
After 2023-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-04 · Exercise / conversion · Disposed 4,984 · Balance 4,984 F1: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024.
Spyre Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.51 · Expires 2036-05-27 | Direct | 8,026 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,026 · Balance 8,026 F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 21:17 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.99 | $0.00 |
DisclosureSEC source: 0001628280-26-063624 · wk-form4_1790371039.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-09-22 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:28 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001859810-26-000003 · wk-form4_1780691291.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2036-06-03 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 27, 2026 Filed May 29, 2026 21:54 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 8,026 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001859810-26-000002 · wk-form4_1780091687.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,026 Underlying: Common Stock · 8,026 shares Expires 2036-05-27 F1 · derivative.exercise_date: This option represents a right to purchase 8,026 shares of the Issuer's common stock, which will vest and become fully exercisable upon the earlier of May 27, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 20:04 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 26,050 | $1.92 | $50,016.00 |
DisclosureSEC source: 0001728117-25-000072 · wk-form4_1755720270.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,050 Read SEC document |
| June 25, 2025 Filed Jun 26, 2025 20:36 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001728117-25-000053 · wk-form4_1750970185.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2035-06-24 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:37 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0001636282-25-000067 · wk-form4_1748896627.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| January 08, 2025 Filed Jan 29, 2025 22:20 UTC Amendment | Aspira Women's Health Inc. AWH · Entity 7871 | Tax withholdingCommon Stock | 6,356 | $0.70 | $4,449.20 |
DisclosureSEC source: 0001859810-25-000002 · primary_doc.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,644 F2 · kind: This line reflects the tax withholding on the vesting of RSUs that vested on December 31, 2024. F5 · kind: This report is being filed to correct the number of shares held after tax withholding on the vesting of RSUs that vested on December 31, 2024. Read SEC document |
| December 31, 2024 Filed Jan 8, 2025 23:35 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001859810-25-000001 · primary_doc.xml · derivative · entry 2 Milligan Sandra · CIK 0001859810 · Interim CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F3 · derivative.exercise_date: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. Read SEC document |
| December 31, 2024 Filed Jan 8, 2025 23:35 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001859810-25-000001 · primary_doc.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Interim CEO & President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on October 28, 2024. Read SEC document |
| December 31, 2024 Filed Jan 29, 2025 22:20 UTC Amendment | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001859810-25-000002 · primary_doc.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Aspira Women's Health Inc. Stock. F4 · derivative.exercise_date: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. F4 · derivative.expiration_date: On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. The common stock into which such vested RSUs converted on December 31, 2024 is reported in Table I on this Form 4. Read SEC document |
| December 31, 2024 Filed Jan 29, 2025 22:20 UTC Amendment | Aspira Women's Health Inc. AWH · Entity 7871 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001859810-25-000002 · primary_doc.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units (RSUs) into common stock. On October 28, 2024, the reporting person was granted 20,000 RSUs, which vested on December 31, 2024. Such RSUs were previously reported in Table II on a Form 4 filed with the SEC on October 28, 2024. Read SEC document |
| November 12, 2024 Filed Nov 14, 2024 01:54 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001859810-24-000005 · primary_doc.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-11-12 Read SEC document |
| October 28, 2024 Filed Oct 28, 2024 22:54 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001859810-24-000004 · primary_doc.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: In accordance with her amended contract effective September 1, 2024, the award will vest 100% on December 31, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. F2 · derivative.expiration_date: In accordance with her amended contract effective September 1, 2024, the award will vest 100% on December 31, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 01:58 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantNon-qualified stock option (Right to Buy) · Derivative | 115,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001728117-24-000066 · wk-form4_1717725502.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2034-06-05 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:10 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 21,980 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0000950170-24-061083 · ownership.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,980 Underlying: Common Stock · 21,980 shares Expires 2034-05-14 F1 · derivative.exercise_date: This option represents a right to purchase 21,980 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| May 03, 2024 Filed May 6, 2024 22:49 UTC | Aspira Women's Health Inc. AWH · Entity 7871 | GrantEMPLOYEE STOCK OPTION (RIGHT TO BUY) · Derivative | 30,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001859810-24-000003 · primary_doc.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: COMMON STOCK · 30,000 shares Expires 2034-05-03 F1 · derivative.exercise_date: The employee stock option will vest in four equal annual amounts beginning April 1, 2025. Read SEC document |
| November 15, 2023 Filed Nov 17, 2023 21:01 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 32,000 | $0.79 | $25,212.80 |
DisclosureSEC source: 0001728117-23-000138 · wk-form4_1700254868.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 32,000 Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001728117-23-000082 · wf-form4_168634167292261.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-07 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028100 · doc4.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,984 Underlying: Common Stock · 4,989 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.exercise_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. F1 · derivative.expiration_date: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:43 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,168 | $24.24 | $52,552.32 |
DisclosureSEC source: 0001209191-23-028100 · doc4.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,599 Read SEC document |
| May 04, 2023 Filed May 8, 2023 22:43 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028100 · doc4.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: 1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On each of May 4, 2022 and May 4, 2023, one-third of the RSUs vested, with the remaining RSUs to vest on May 4, 2024. Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027173 · doc4.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,899 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:06 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 826 | $24.63 | $20,344.38 |
DisclosureSEC source: 0001209191-23-027173 · doc4.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,783 Read SEC document |
| May 01, 2023 Filed May 3, 2023 23:06 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,899 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-027173 · doc4.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested, and on May 1, 2023, the remaining 50% of the RSUs vested. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 104,961 | $0.00 Strike: $23.52 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · derivative · entry 5 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,961 Underlying: Common Stock · 104,961 shares Expires 2033-03-31 F5 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 29,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · derivative · entry 4 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,230 Underlying: Common Stock · 29,230 shares Expires 2026-03-31 F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2024, March 31, 2025 and March 31, 2026. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 5,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,928 Underlying: Common Stock · 5,964 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. F2 · derivative.expiration_date: On March 31, 2023, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,115 | $23.09 | $48,835.35 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,710 Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:18 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 5,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023078 · doc4.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,825 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:29 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 7,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014842 · doc4.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,976 shares Expires 2022-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F3 · shares: The amount of Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2022. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2023. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:29 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,346 | $25.09 | $58,861.14 |
DisclosureSEC source: 0001209191-23-014842 · doc4.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,861 Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:29 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 7,976 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014842 · doc4.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit converts into one share of Organon & Co. common stock. Read SEC document |
| June 09, 2022 Filed Jul 15, 2022 21:03 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001728117-22-000069 · wf-form4_165791902180593.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-08 F1 · shares: Award made pursuant to Non-Employee Director Compensation Program. F2 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 4,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056628 · tm2214603-4_4seq1.xml · derivative · entry 6 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,984 Underlying: Common Stock · 4,984 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F3 · derivative.exercise_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. F3 · derivative.expiration_date: On May 4, 2022, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on May 4, 2023 and May 4, 2024. Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:47 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 1,806 | $32.44 | $58,586.64 |
DisclosureSEC source: 0001104659-22-056628 · tm2214603-4_4seq1.xml · nonDerivative · entry 4 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,231 Read SEC document |
| May 04, 2022 Filed May 6, 2022 00:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 4,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056628 · tm2214603-4_4seq1.xml · nonDerivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-056628 · tm2214603-4_4seq1.xml · derivative · entry 5 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,842 Underlying: Common Stock · 1,842 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:47 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 525 | $32.08 | $16,842.00 |
DisclosureSEC source: 0001104659-22-056628 · tm2214603-4_4seq1.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,053 Read SEC document |
| May 03, 2022 Filed May 6, 2022 00:47 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-056628 · tm2214603-4_4seq1.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055430 · tm2214297-4_4seq1.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,896 Underlying: Common Stock · 1,896 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F2 · shares: The amount of the RSUs has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:40 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 540 | $32.33 | $17,458.20 |
DisclosureSEC source: 0001104659-22-055430 · tm2214297-4_4seq1.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,736 Read SEC document |
| May 01, 2022 Filed May 3, 2022 23:40 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 1,896 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055430 · tm2214297-4_4seq1.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. On May 1, 2022, 50% of the RSUs vested with the remaining 50% of the RSUs to vest on May 1, 2023. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:06 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (right to buy) · Derivative | 55,114 | $0.00 Strike: $34.93 | $0.00 |
DisclosureSEC source: 0001104659-22-042359 · tm2211465-4_4seq1.xml · derivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,114 Underlying: Common Stock · 55,114 shares Expires 2032-03-29 F3 · derivative.exercise_date: The Reporting Person was granted stock options, which vest and become exercisable in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 22:06 UTC | Organon & Co. OGN · Entity 4115 | GrantRestricted Stock Units · Derivative | 17,892 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042359 · tm2211465-4_4seq1.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,892 Underlying: Common Stock · 17,892 shares Expires 2025-03-31 F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon & Co. ("Organon") common stock for each RSU. F2 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 31, 2023, March 31, 2024 and March 31, 2025. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionRestricted Stock Units · Derivative | 10,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-029457 · tm228175-5_4seq1.xml · derivative · entry 3 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,171 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit converts into one share of Organon & Co. common stock. F2 · date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F3 · shares: The amount of the Restricted Stock Units has been slightly adjusted from the Reporting Person's Form 4, dated June 4, 2021, based on the finalization of certain calculations. F2 · derivative.exercise_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. F2 · derivative.expiration_date: As originally reported on the Form 4, dated June 4, 2021, these Restricted Stock Units vested on December 31, 2021. These Restricted Stock Units were subsequently distributed to the Reporting Person on February 28, 2022. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Organon & Co. OGN · Entity 4115 | Tax withholdingCommon Stock | 2,941 | $37.57 | $110,493.37 |
DisclosureSEC source: 0001104659-22-029457 · tm228175-5_4seq1.xml · nonDerivative · entry 2 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,380 Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 23:46 UTC | Organon & Co. OGN · Entity 4115 | Exercise / conversionCommon Stock | 10,171 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-029457 · tm228175-5_4seq1.xml · nonDerivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converts into one share of Organon & Co. common stock. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:14 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 22,321 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0000899243-21-033677 · doc4.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,321 Underlying: Common Stock · 22,321 shares Expires 2031-08-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on August 17, 2022, August 17, 2023 and August 17, 2024. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:26 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001728117-21-000074 · wf-form4_162370598998133.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| June 02, 2021 Filed Jun 5, 2021 01:27 UTC | Organon & Co. OGN · Entity 4115 | GrantStock Option (Right to Buy) · Derivative | 115,980 | $0.00 Strike: $36.11 | $0.00 |
DisclosureSEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 13 Milligan Sandra · CIK 0001859810 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,980 Underlying: Common Stock · 115,980 shares Expires 2031-05-03 F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations. F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.